Quanterix (NASDAQ:QTRX - Get Free Report) is scheduled to post its quarterly earnings results after the market closes on Tuesday, May 7th. Analysts expect Quanterix to post earnings of ($0.33) per share for the quarter. Quanterix has set its FY 2024 guidance at EPS.Individual that wish to listen to the company's earnings conference call can do so using this link.
Quanterix (NASDAQ:QTRX - Get Free Report) last issued its quarterly earnings data on Thursday, February 29th. The company reported ($0.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($0.05). Quanterix had a negative net margin of 26.42% and a negative return on equity of 9.15%. The business had revenue of $31.55 million during the quarter, compared to analyst estimates of $27.92 million. On average, analysts expect Quanterix to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Quanterix Price Performance
Shares of Quanterix stock traded up $0.54 on Tuesday, hitting $16.12. The company had a trading volume of 478,277 shares, compared to its average volume of 351,413. Quanterix has a twelve month low of $12.17 and a twelve month high of $29.70. The stock has a 50-day moving average of $22.53 and a 200-day moving average of $23.28. The firm has a market capitalization of $616.59 million, a P/E ratio of -18.90 and a beta of 1.30.
Insider Buying and Selling
In other news, Director Laurie J. Olson sold 1,500 shares of the business's stock in a transaction dated Wednesday, February 14th. The shares were sold at an average price of $24.35, for a total value of $36,525.00. Following the completion of the sale, the director now owns 15,238 shares of the company's stock, valued at $371,045.30. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 8.20% of the stock is owned by insiders.
Analyst Ratings Changes
Several research firms have recently weighed in on QTRX. Canaccord Genuity Group reduced their price objective on Quanterix from $32.00 to $25.00 and set a "buy" rating for the company in a research report on Monday. Scotiabank lifted their price objective on shares of Quanterix from $30.00 to $32.00 and gave the company a "sector outperform" rating in a report on Monday, March 4th. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Buy" and an average target price of $30.60.
Get Our Latest Stock Report on QTRX
About Quanterix
(
Get Free Report)
Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.
Read More
Before you consider Quanterix, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Quanterix wasn't on the list.
While Quanterix currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
